1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A

CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A

SSZSE:000908
5.35
CNY
+0.06
(+1.13%)
9.71BMarket Cap
CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A
SZSE:000908
(Shenzhen Stock Exchange)

Recent

price

5.35

P/E

ratio

- -

div

yld

0.06%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.71
0.45
0.47
2.77
3.9
2.81
3
2.94
2.94
1.53
1
0.92
0.96
0.75
0.47
0.43
- -
Revenue per Share
0.01
-0.19
-0.2
0.26
0.5
0.37
0.39
0.18
0.19
-1.01
-1.1
-0.17
-0.14
-0.27
0.17
-0.09
- -
Basic EPS, GAAP
-0.06
-0.04
-0.02
-0.16
0.21
-0.15
-0.27
-0.17
0.2
-0.09
-0.42
0.1
0.12
0.03
-0.01
0.06
- -
Free Cash Flow per Basic Share
0.03
0.01
- -
0.1
0.06
0.06
0.15
0.1
0.12
0.1
0.1
0.1
0.05
0.03
0.02
0.01
- -
Dividend per Share
0.19
- -
-0.2
2.52
1.21
2.46
2.72
2.7
2.8
1.77
0.47
0.33
0.19
-0.08
0.09
0.03
1.19
Book Value per Share
0.04
-0.19
-0.39
1.74
0.73
1.6
1.73
1.61
1.56
0.86
0.11
0.05
-0.08
-0.27
-0.09
-0.15
1.1
Tangible Book Value per Share
308
308
308
513
502
876
880
880
880
880
880
880
880
880
880
880
1,097
Basic Weighted Avg Shares
217
139
145
1,419
1,957
2,459
2,641
2,584
2,586
1,344
878
811
841
657
416
378
- -
Sales/Revenue/Turnover
-4.79
-24.84
-16.93
15.2
16.83
19.18
19.33
13.45
12.94
-41.86
-58.55
-31.77
2.06
-11.78
-0.79
-7.38
- -
Operating Margin (%)
10
9
9
24
27
42
60
73
93
76
81
107
55
44
29
31
- -
Depreciation Expense
3
-57
-61
135
251
324
340
157
169
-890
-969
-153
-123
-236
152
-81
- -
Net Income, GAAP
3.38
- -
- -
16.06
15.9
14.64
17.53
26.39
19.99
- -
- -
- -
- -
- -
3.09
- -
- -
Effective Tax Rate (%)
1.38
-40.98
-41.85
9.53
12.82
13.18
12.88
6.08
6.55
-66.23
-110.43
-18.83
-14.58
-35.94
36.61
-21.39
- -
Profit Margin (%)
-47
-213
-268
334
273
958
1,905
1,534
1,207
115
-837
-684
-512
-828
-678
-526
1,508
Working Capital
115
- -
- -
45
56
161
1,170
1,183
874
389
- -
9
82
95
7
6
5
LT Debt
58
1
-60
775
994
2,242
2,612
2,595
2,840
1,912
609
309
202
-175
-15
-28
2,032
Total Equity
-6.41
- -
- -
27.52
18.97
15.51
9.44
4.07
4.16
- -
- -
- -
- -
- -
60.85
- -
- -
Return on Invested Capital (%)
5.17
- -
- -
23.63
20.93
14.41
9.28
4.51
5.01
- -
- -
- -
- -
- -
42.59
- -
- -
Return on Capital (%)
5.39
-197.76
- -
- -
28.58
20.59
14.92
6.6
7.01
-44.29
-98.32
-43.52
-54.11
- -
- -
-154.16
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
87
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
880
1,760
1,760
Market Capitalization
6,326
13,637
9,713

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
275
1,964
1,881
Cash, Cash Equivalents & STI
76
1,751
1,653
Accounts Receivable, Net
45
60
58
Inventories
39
35
51
Total Current Liabilities
802
439
374
Payables & Accruals
- -
- -
- -
ST Debt
87
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-35.08%
-55.06%
86.71%
Free Cash Flow
-113.11%
-238.17%
-889.88%
Net Income, GAAP
-98.63%
-65.8%
-153.11%
Sales/Revenue/Turnover
-14.9%
-14.32%
-9.11%
Total Cash Common Dividend
-3.52%
-31.86%
-21.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
102
92
121
416
2025
100
83
- -
106
378
2026
108
95
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.04
-0.02
0.23
0.17
2025
-0.01
-0.02
- -
-0.04
-0.09
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.01
2026
0.01
-0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hunan Jingfeng Pharmaceutical Co., Ltd. (000908.SZ) engages in the research, development, manufacture, and sale of pharmaceutical products primarily focused on anti-tumor, anti-infective, and cardiovascular medications. The company offers a diverse portfolio of branded generics and innovative drugs, including the flagship anti-tumor agent podophyllotoxin injections under the Jingfukang brand; cephalosporin antibiotics such as cefminox sodium for anti-infective treatments; cardiovascular therapies like metoprolol tartrate extended-release tablets and amlodipine besylate capsules; as well as respiratory drugs including budesonide inhalation suspensions and salmeterol xinafoate fluticasone propionate powder for inhalation; and supportive care products like alprostadil injections for microcirculation improvement. These products target hospitals, pharmacies, and distributors serving patients with chronic and acute conditions. Founded in 1993 and headquartered in Changsha, Hunan province, China, the company operates principally within the domestic Chinese market, with manufacturing facilities in Hunan and distribution networks across major provinces. Hunan Jingfeng Pharmaceutical serves as a key player in China's generic pharmaceutical sector, emphasizing cost-effective alternatives to patented drugs while investing in bioequivalence studies and regulatory compliance for National Medical Insurance listings. It maintains subsidiaries for R&D and sales, with no disclosed parent company relationships. In the past two years, the company has pursued strategic expansions including the commercial launch of several new generic drugs approved by China's National Medical Products Administration (NMPA), such as generic versions of rivaroxaban tablets for anticoagulation therapy in 2024 and expanded production capacity for its core anti-tumor pipeline amid rising oncology demand. Hunan Jingfeng announced a partnership with regional distributors in 2025 to enhance market penetration in central and western China, alongside a RMB 150 million funding initiative for facility upgrades and R&D in biosimilars. No major acquisitions, name changes, or reorganizations have been reported recently, though the firm reported steady revenue growth driven by volume increases in high-margin injectables.